Your browser doesn't support javascript.
loading
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes.
Yildiz, Anil; Bilici, Ahmet; Acikgoz, Ozgur; Hamdard, Jamshid; Basim, Pelin; Cakir, Tansel; Cakir, Asli; Olmez, Omer Fatih; Gezen, Cem; Yildiz, Ozcan.
Afiliación
  • Yildiz A; Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, Istanbul, Turkey.
  • Bilici A; Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, Istanbul, Turkey.
  • Acikgoz O; Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, Istanbul, Turkey.
  • Hamdard J; Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, Istanbul, Turkey.
  • Basim P; Department of Breast Surgery, Istanbul Medipol University, Istanbul, Turkey.
  • Cakir T; Department of Nuclear Medicine, Istanbul Medipol University, Istanbul, Turkey.
  • Cakir A; Department of Pathology, Istanbul Medipol University, Istanbul, Turkey.
  • Olmez OF; Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, Istanbul, Turkey.
  • Gezen C; Department of Breast Surgery, Istanbul Medipol University, Istanbul, Turkey.
  • Yildiz O; Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, Istanbul, Turkey.
J Chemother ; : 1-9, 2024 Feb 13.
Article en En | MEDLINE | ID: mdl-38351652
ABSTRACT
The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to 2019, a total of 139 patients who were histologically confirmed to have breast cancer, underwent NAC, and subsequently received breast and axillary surgery, were retrospectively included in this study. The rates of pathological complete response (pCR) to NAC were significantly higher for HER2-positive and triple-negative subtypes than for luminal A and HER2-negative subtypes (p = 0.013). Multivariate analysis for disease-free survival (DFS) revealed that tumour grade and the presence of pCR were independent prognostic factors. The presence or absence of a pCR with NAC was an independent prognostic indicator in the multivariate analysis for overall survival (OS). Lastly, achieving a pCR was independently predicted by 18F-FDG PET/CT findings, the HER2-positive subtype, and the triple-negative subtype. Despite the inherent methodological limitations, our findings underscore the significance of identifying predictive markers to tailor NAC plans, with the aim of improving survival outcomes.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Chemother Asunto de la revista: ANTINEOPLASICOS / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Chemother Asunto de la revista: ANTINEOPLASICOS / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Reino Unido